Understanding of the mechanisms of Long Covid has advanced because of human and animal model studies and clinical trials.

Animal models will inform our understanding of Long Covid and will aid in identifying therapeutic targets.

A multiomic analysis reveals sex differences and immune correlates of Long Covid symptom development, persistence, and resolution.

Nasal IgA1 autoantibodies against IFN-α are associated with better COVID-19 prognosis, including fewer symptoms and robust anti–SARS-CoV-2 immunity.

Alternating expression of cerebellar Aldoc/zebrin-II is lost in mouse models of polyglutamine ataxias and altered in the cerebella of patients with SCA7.

Anti–spike protein monoclonal antibodies alter endogenous humoral immunity to SARS-CoV-2 in mice, nonhuman primates, and humans.

The R1441C-Lrrk2 mutation causes age-acquired immune exhaustion in mouse macrophages in a sex-dependent manner.

Blocking nociceptor CGRP to RAMP1 signaling in macrophages reduces endometriosis pain and lesion growth in a mouse model of the disease.

Integrative multiomic analysis identifies three molecular subtypes of NAFLD associated with distinct clinical risks.

Emerging CAR-T technologies offer transformative potential to address the needs of patients with autoimmunity or other diseases beyond cancer.

Protumoral foamy macrophages are associated with poorer survival in humans with glioblastoma and can be targeted by lipid droplet inhibitors.

A fasting-mimicking diet treatment restores renal function in glomerulopathy and provides preliminary evidence of beneficial effects in chronic kidney disease.

Statistical modeling allows the classification of individual tumor responses and assessment of treatment effects with heterogeneous response.

A granulovacuolar degeneration–associated form of necroptosis represents an Alzheimer’s disease–related type of nerve cell death that can be inhibited.

A single-cell transcriptomic atlas with integrated proteomics for the prefrontal cortex of late-stage Parkinson’s disease human brains is presented.

Current COVID-19 vaccines induce suboptimal respiratory mucosal immunity even after mRNA boosters (Declercq et al. and Lasrado et al., this issue).

COVID-19 mRNA booster vaccines induce limited mucosal immunity.

mRNA booster vaccines for SARS-CoV-2 induce circulating virus neutralizing antibodies that may enter the respiratory mucosa.

Mutation load and clonal hematopoiesis are similar between donors and recipients, even decades after hematopoietic cell transplantation.

Stromal reprograming by FAK inhibition overcomes RAS-MAPK inhibition resistance and enhances responses to therapy in pancreas cancer models.